WellSIM Biomedical Technologies is a life-science technology company supported by Illumina Accelerator. The company specializes in state-of-the-art extracellular vesicle analysis technology, designed for both research and clinical applications.

We are currently offering early access custom services for high-speed and high-sensitivity EV surface marker analysis utilizing our ExoDot technology. Our goal is to develop a fully integrated and automatic system based on this technology. We are developing this platform for cost-effective, highly accurate diagnosis of Alzheimer's disease.

Extracellular vesicles are small lipid bilayer particles that contain a variety of biomolecules, including lipids, proteins, and nucleic acids. They are produced by most cell types and can be found in almost all bodily fluids. EVs play a crucial role in cellular communication and signaling, with significant physiological and pathological implications. By examining EV-derived biomarkers, such as DNA, RNA, protein, and lipid profiles, it is possible to detect and diagnose a range of diseases, including cancers, neurodegenerative and autoimmune diseases. Additionally, EVs are emerging as an innovative therapeutic platform, capable of delivering therapeutic materials directly to target tissues and cells.